Dr. Thomas Colletti, DHSc, PA-C, DFAAPA
Purpose: The purpose of this article is to discuss a case presentation of a rare form of acquired Hemophagocytic Lymphohistiocytosis (HLH) and review the standard of care in addition to current therapeutic options for the disease.
Method: A PubMed literature search conducted with search terms hemophagocytic lymphohistiocytosis, guidelines, survival, treatment, and EBV, allowed for the review and reference to nine applicable sources for this case presentation.
Results: Increased observation of young adults with relapsed or refractory secondary HLH is needed to evaluate for remission with a new monoclonal antibody (mAb) therapy versus standard of care chemotherapeutic protocols with stem cell transplant.
Conclusion: The patient is currently under active surveillance for relapse and possible treatment with emapalumab for secondary HLH to determine if remission-cure can be achieved. Emapalumab is a monoclonal antibody recently approved to treat relapsed and refractory sHLH.
Bonanno L, Kiner-Strachan B, Zaslav A, Delaney K, Ginebra C. HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS CASE PRESENTATION. University of Lynchburg DMSc Doctoral Project Assignment Repository. 2019; 1(4).
Available when accessing via a campus IP address or logged in with a University of Lynchburg email address.
Off-campus users can also use 'Off-campus Download' button above for access.